FEB 23, 2017 09:00 AM PST

Metabolomics and its Role in Precision Medicine

4 2 190

  • President and Chief Executive Officer, Metabolon
      Dr. John Ryals co-founded Metabolon, Inc. in 2002 and serves as president and CEO. Metabolon is a pioneer and leader in the field of metabolomics and its use in precision medicine and human health. Prior to Metabolon, he was a co-founder, CEO and president of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years' experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.


    Although there have been enormous advances in gene sequencing, the results give massive amounts of data that only point to disease risk. Major health factors, including diet, lifestyle, environment and genes, exert their influence by subtly changing our metabolic composition. Metabolomics provides a snapshot of the current state of health and provides new information to help with immediate clinical decision-making. 

    Advances in metabolomics have made it a valuable first-line tool for assessing health. It can be used to identify perturbations of metabolic pathways associated with many diseases and quickly screen patients for health or disease status. In this session, we’ll discuss the technology and how it is guiding precision medicine today and its role in the future.

    Show Resources
    Loading Comments...